



#36970

DATE: JUNE 23, 2015

SUBJECT: SYNAGEVA BIOPHARMA CORPORATION – CONTRACT
ADJUSTMENT
OPTION SYMBOL: 6/23/15 - GEVA remains GEVA
6/24/15 - GEVA becomes ALXN1
DATE: 6/23/15
* * * EFFECTIVE IMMEDIATELY * * *

On June 19, 2015, Pulsar Merger Sub Inc., a wholly owned subsidiary of Alexion Pharmaceuticals, Inc. (ALXN), completed its exchange offer for Synageva BioPharma Corporation (GEVA) Common Shares. The subsequent acquisition of Synageva BioPharma Corporation was consummated before the opening on June 23, 2015.

CONTRACT ADJUSTMENT

DATE: June 23, 2015

OPTION SYMBOL: 6-23-15 GEVA remains GEVA (with adjusted deliverable below)
6-24-15 GEVA becomes ALXN1

STRIKE DIVISOR: 1

CONTRACT MULTIPLIER: 1

NEW MULTIPLIER: 100 (e.g., for premium or strike price extensions, 1.00 equals \$100)

NEW DELIVERABLE PER CONTRACT: 1) 65 Alexion Pharmaceuticals, Inc. (ALXN) Common Shares
2) Cash in lieu of 0.81 fractional ALXN shares
3) \$11,500.00 Cash

CUSIP: ALXN: 015351109

PRICING

Until the cash in lieu amount is determined, the underlying price for ALXN1 will be determined as follows:

$$ALXN1 = 0.6581 (ALXN) + 115.00$$

DELAYED SETTLEMENT

The ALXN component of the ALXN1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash component of the ALXN1 deliverable until the cash in lieu amount is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by a panel of The OCC Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.